A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Inclusion Criteria:

- Have a histologically confirmed diagnosis of STS for which olaratumab and doxorubicin
would be appropriate therapy. Participants with a diagnosis of Grade 1 liposarcoma are
eligible if there is histological or radiographic evidence of evolution to more
aggressive disease. Participants with Kaposi's sarcoma and gastrointestinal stromal
tumors (GIST) will be excluded. Participants must have potentially resectable disease
(as assessed by the study investigator) and have a primary tumor lesion deemed
amenable to serial biopsy.

- For radiotherapy addendum only: Have a histologically confirmed diagnosis of STS of
the extremities, Grade 2 or 3, >5 centimeters, for which olaratumab and radiotherapy
would be appropriate therapy. Participants with Kaposi's sarcoma, GIST or myxoid
liposarcoma will be excluded.

- Have consented to undergo mandatory serial peripheral whole blood and tumor tissue
sampling.

Exclusion Criteria:

- Have active central nervous system (CNS) or leptomeningeal metastasis (brain
metastasis) at the time of enrollment. Participants with a history of a CNS metastasis
previously treated with curative intent (for example, stereotactic radiation or
surgery) that have not progressed on follow-up imaging, have been asymptomatic for at
least 60 days and are not receiving systemic corticosteroids and or/anticonvulsants,
are eligible. Participants with signs or symptoms of neurological compromise should
have appropriate radiographic imaging performed before enrollment to rule out brain
metastasis.

- Have received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other
anthracyclines or anthracenediones; the participant has received treatment with
olaratumab or has participated in a prior olaratumab trial.

- For radiotherapy addendum only: Have received previous radiotherapy in the primary
tumor lesion and/or prior treatment with olaratumab or has participated in a prior
olaratumab trial.